A mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) model for omalizumab (rhuMAb-E25).

被引：0
|
作者：
Sun, YN [1 ]
Marian, M [1 ]
Schoenhoff, M [1 ]
Sinclair, D [1 ]
Fick, R [1 ]
机构：
[1] Genentech Inc, S San Francisco, CA 94080 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2001年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P87 / P87
页数：1
相关论文
共 50 条
  • [21] Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
    Ng, Chee M.
    Patnaik, A.
    Beeram, M.
    Lin, C. C.
    Takimoto, C. H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (05) : 985 - 994
  • [22] Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model
    Lin, Yu-Wei
    Zhou, Qi Tony
    Han, Mei-Ling
    Onufrak, Nikolas J.
    Chen, Ke
    Wang, Jiping
    Forrest, Alan
    Chan, Hak-Kim
    Li, Jian
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (03)
  • [23] Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
    Chee M. Ng
    A. Patnaik
    M. Beeram
    C. C. Lin
    C. H. Takimoto
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 985 - 994
  • [24] Mechanism-based pharmacokinetic model for paclitaxel
    Henningsson, A
    Karlsson, MO
    Viganò, L
    Gianni, L
    Verweij, J
    Sparreboom, A
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (20) : 4065 - 4073
  • [25] Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25
    不详
    BioDrugs, 2002, 16 (5) : 380 - 386
  • [26] Population pharmacokinetic (PK)-pharmacodynamic (PD) model for gefitinib in cancer patients.
    Li, J
    Karlsson, MO
    Brahmer, J
    Cusatis, G
    Hidalgo, M
    Baker, SD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 212S - 212S
  • [27] A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip
    Sung, Jong Hwan
    Kam, Carrie
    Shuler, Michael L.
    LAB ON A CHIP, 2010, 10 (04) : 446 - 455
  • [28] Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in healthy subjects.
    Van Wart, SA
    Cirincione, BB
    Ludwig, EA
    Chen, X
    Shoaf, S
    Grasela, TH
    Mallikaarjun, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P60 - P60
  • [29] Mechanism-based PK-PD model for Brain Dopamine Responses by Methylphenidate in Rats
    Shimizu, Ryosuke
    Horiguchi, Naotaka
    Yano, Koji
    Sakuramoto, Masashi
    Kanegawa, Naoki
    Shinohara, Shunji
    Ohnishi, Shuichi
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S106 - S106
  • [30] DEVELOPMENT OF A PHARMACOKINETIC (PK)/PHARMACODYNAMIC (PD) MODEL TO EVALUATE THE IMPACT OF PK VARIATION ON PD FOR EXTENDED RELEASE METOPROLOL FORMULATIONS
    Sharma, V. D.
    Trame, M. N.
    Schmidt, S.
    Fang, L. L.
    Lesko, L. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S9 - S9
12345